Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
69 hedge funds and large institutions have $1.23B invested in Rubius Therapeutics, Inc in 2019 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 30 increasing their positions, 15 reducing their positions, and 9 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 15
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
3% more funds holding
Funds holding: 67 → 69 (+2)
10% less capital invested
Capital invested by funds: $1.37B → $1.23B (-$134M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$11.9M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$11.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.92M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.92M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$3.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$7.87M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.95M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1.44M |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$1.31M |
| 5 |
AG
Artal Group
Luxembourg
|
-$1.21M |
RUBY Hedge Fund Activity: Q2 2019 in Review
69 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q2 2019, worth a combined $1.23B — down 9.8% from $1.37B a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new RUBY positions and 9 closed out — a net gain of 4 holders — while 30 added to existing stakes and 15 trimmed.
The largest buyer was Sumitomo Mitsui Trust Group, adding an estimated $11.9M. The largest seller was Franklin Resources, exiting entirely with an estimated $7.87M sold.
- 69 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q2 2019, up from 67 in Q1 2019.
- Funds reported $1.23B of Rubius Therapeutics, Inc stock for Q2 2019, down 9.8% quarter-over-quarter.
- 13 funds opened new Rubius Therapeutics, Inc positions in Q2 2019 and 9 closed out, a net change of +4 holders.
- The largest Rubius Therapeutics, Inc buyer in Q2 2019 was Sumitomo Mitsui Trust Group, an estimated $11.9M added.
- The largest Rubius Therapeutics, Inc seller in Q2 2019 was Franklin Resources, an estimated $7.87M sold.
Based on aggregated 13F filings for Q2 2019.